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Abstract
Background: Infection with Wuchereria bancrofti can cause severe disease characterized by subcutaneous fibrosis and
extracellular matrix remodeling. Matrix metalloproteinases (MMPs) are a family of enzymes governing extracellular
remodeling by regulating cellular homeostasis, inflammation, and tissue reorganization, while tissue-inhibitors of
metalloproteinases (TIMPs) are endogenous regulators of MMPs. Homeostatic as well as inflammation-induced balance
between MMPs and TIMPs is considered critical in mediating tissue pathology.
Methods: To elucidate the role of MMPs and TIMPs in filarial pathology, we compared the plasma levels of a panel of MMPs,
TIMPs, other pro-fibrotic factors, and cytokines in individuals with chronic filarial pathology with (CP Ag+) or without (CP
Ag2) active infection to those with clinically asymptomatic infections (INF) and in those without infection (endemic normal
[EN]). Markers of pathogenesis were delineated based on comparisons between the two actively infected groups (CP Ag+
compared to INF) and those without active infection (CP Ag2 compared to EN).
Results and Conclusion: Our data reveal that an increase in circulating levels of MMPs and TIMPs is characteristic of the
filarial disease process per se and not of active infection; however, filarial disease with active infection is specifically
associated with increased ratios of MMP1/TIMP4 and MMP8/TIMP4 as well as with pro-fibrotic cytokines (IL-5, IL-13 and TGF-
b). Our data therefore suggest that while filarial lymphatic disease is characterized by a non-specific increase in plasma
MMPs and TIMPs, the balance between MMPs and TIMPs is an important factor in regulating tissue pathology during active
infection.
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Introduction
Lymphatic filariasis (LF) is characterized by dysfunction of
lymphatics that can lead to severe and often irreversible
lymphedema and elephantiasis [1,2]. The critical factor in the
development of host pathology appears to reflect the parasite-
mediated initiation of a cascade of events that leads to tissue
fibrosis and scarring [2,3]. It is assumed that both parasite
products and the host inflammatory response lead to lymphatic
dysfunction and lymphangiogenesis that, in turn, predisposes
infected individuals to secondary bacterial and fungal infection
[2,4,5]. Host-parasite interactions as well as secondary infections
then trigger inflammatory reactions in the skin and subcutaneous
tissue with underlying fibrosis and cellular hyperplasia processes
resulting in lymphedema and elephantiasis [2,4]. Typically in
Wuchereria or Brugia infections, disease manifests years after
exposure, while clinically asymptomatic infection is not only more
common but can also occur at a relatively young age [1].
Although lymphatic dysfunction and localized/systemic immu-
nologic and inflammatory responses are important features of
lymphatic pathology [6], perturbations in extracellular matrix
(ECM) architecture and subsequent remodeling are also associated
with filarial disease [7–9]. Chronic inflammation, as seen in LF
disease, causes an excessive accumulation of ECM components
(such as collagen) that can contribute to fibrotic scarring [2].
Patent filarial infections are typically associated with Type 2 and
regulatory cytokine responses, but some of these are also pro-
fibrotic, especially IL-5, IL-13, and TGF-b [10], which are known
to influence collagen deposition and ECM remodeling [11].
The turnover of collagen and other ECM proteins is controlled
by a large family of proteolytic enzymes called matrix metallo-
proteinases (MMPs) and their inhibitors (tissue inhibitors of
metalloproteinases [TIMPs]), produced by a variety of cell types
including macrophages, granulocytes, epidermal cells, and fibro-
blasts [12–14]. Tissue immunopathology is known to be associated
with dysregulation of MMPs and TIMPs in several infections,
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including viral, bacterial, spirochetal, protozoan, fungal, and
parasitic infections [15]. The MMP family consists of more than
26 different proteases that differ in their tissue expression/
localization and target specificity, while the TIMP family consists
of four ubiquitously expressed proteins (TIMP1–4) [12–14]. In
addition, other factors such as fibroblast growth factor (FGF) and
platelet-derived growth factor (PDGF) are known mediators of
tissue fibrosis [11].
Although the importance of tissue fibrosis in the pathology
associated with LF is well known [3], the molecular mechanisms
underlying the fibrotic process in filariasis has not been well
established. We therefore sought to delineate the role of the factors
known to regulate fibrosis and tissue remodeling in filarial disease
development. Our data suggest that while elevated circulating
levels of MMPs and TIMPs are characteristic of filarial disease, it
is the increased ratios of certain MMPs to TIMPs (associated with
elevated pro-fibrotic cytokines) that is specifically associated with
the pathogenesis of disease in LF.
Methods
Study population
We studied a group of 91 individuals with filarial lymphedema
without active filarial infection (hereafter CP Ag2), 28 individuals
with filarial lymphedema with active filarial infection (hereafter CP
Ag+), 90 asymptomatic or subclinical, infected individuals
(hereafter INF), and 80 uninfected, endemic normal individuals
(hereafter EN) in an area endemic for LF in Tamil Nadu, South
India (Table 1). Diagnosis of active filarial infection was performed
by measuring circulating filarial antigen levels by both the ICT
filarial antigen test (Binax, Portland, ME, USA) and the TropBio
Og4C3 enzyme-linked immunosorbent assay (ELISA) (Trop Bio
Pty. Ltd, Townsville, Queensland, Australia) and all the infected
individuals were positive by both circulating antigen assays. All CP
Ag2 individuals had undergone treatment with repeated doses of
diethylcarbamazine. All of the CP individuals had early stage
lymphedema (Grades 1 and 2) only, and individuals with
concurrent overt and active bacterial infection were excluded
from the study. Only 28 CP Ag+ individuals were detected after
screening over 1000 individuals with chronic pathology reflecting
the rarity of this group in an endemic area. Platelet-poor plasma
samples collected using heparin tubes were used for the entire
study. All samples were obtained after centrifugation of heparin-
ized whole blood and were stored at 280uC. A subset of
individuals in each group (chosen consecutively) was used to
measure the various parameters by multiplex immunoassays, and
the number of individuals used in each group is indicated in the
figure legends. All individuals were examined as part of a clinical
protocol approved by Institutional Review Boards of both the
National Institute of Allergy and Infectious Diseases and the Tubercu-
losis Research Center (NCT00375583 and NCT00001230);
informed written consent was obtained from all participants.
Measurement of MMPs and TIMPs
MMPs were measured using the Fluorokine MAP Multiplex
Assay (R&D Systems, Minneapolis, MN, USA), which is a bead
based assay, run on a LuminexH ELISA platform. For preliminary
experiments, plasma samples were assayed for MMP-1, MMP-2,
MMP-3, MMP-7, MMP-8, MMP-9, MMP-11, and MMP-12.
Because the levels of MMP-2, -3, -11, and -12 were below the
threshold for detection, subsequent studies were carried out using
a panel of MMP-1, -7, -8, and -9. The MMP panel measures pro,
mature and TIMP-1 complexed MMP-1, 7, 8 and 9. TIMP-1,
TIMP-2, TIMP-3, and TIMP-4 levels were measured using the
Fluorokine MAP Multiplex Assay (R&D Systems), according to
the manufacturer’s instructions.
Cytokines and other pro-fibrotic factors
Plasma levels of cytokines IL-5 and IL-13 were measured using
the BioplexH multiplex ELISA system. Plasma levels of fibroblast
growth factor-2 (FGF-2) and platelet-derived growth factor-AA
(PDGF-AA) were measured using the Milliplex MAP kit system
(Millipore, Billerica, MA, USA). Plasma levels of active TGF-b
were measured using an R&D ELISA kit.
Statistical analysis
Data analyses were performed using GraphPad PRISM
(GraphPad Software, Inc., San Diego, CA, USA). Geometric
means (GM) were used for measurements of central tendency.
Statistically significant differences between two groups were
Author Summary
Lymphatic filariasis afflicts over 120 million people world-
wide. While the infection is mostly clinically asymptomatic,
approximately 40 million people suffer from overt, morbid
clinical pathology characterized by swelling of the scrotal
area and lower limbs (hydrocele and lymphedema). Host
immunologic factors that influence the pathogenesis of
disease in these individuals are not completely under-
stood. Matrix metalloproteinases are a family of circulating
and tissue proteins that influence the development of
tissue fibrosis. They are regulated by another family of
proteins called tissue inhibitors of metalloproteinases. The
interplay between these proteins governs tissue fibrosis in
a variety of conditions. In addition, certain cytokines are
known to promote pro-fibrotic events. We have attempted
to elucidate the role of the above-mentioned factors in
disease pathogenesis by comparing the plasma levels of
the various markers in four groups of individuals: chronic
pathology individuals with or without active filarial
infection; asymptomatic, filaria-infected individuals; and
uninfected, endemic normal individuals. We show that
altered ratios of the metalloproteinases and their inhibi-
tors—as well as elevated levels of pro-fibrotic cytokines—
characterize filarial infection-induced lymphatic pathology.
Table 1. Characteristics of the study population.
Endemic Normal (EN) (n=80) Infected (INF) (n=90) Chronic Pathology (CP Ag+) (n=28) Chronic Pathology (CPAg2) (n=91)
Age 26 (20–50) 36 (15–73) 44 (18–69) 38 (17–70)
Gender M / F 44 / 36 44 / 46 19 / 9 47 / 44
CFA (Units/ml) Range ,32 3126 (136–32000) 1606 (464–8996) ,32
doi:10.1371/journal.pntd.0001681.t001
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analyzed using the nonparametric Mann-Whitney U test. Corre-
lations were calculated by the Spearman rank correlation test.
Results
CP individuals exhibit increased circulating levels of
MMPs, independent of infection status
To determine the association of MMPs with filarial lymphede-
ma, we measured the plasma levels of MMP-1, -7, -8, and -9 in CP
Ag+, INF, CP Ag2, and EN. As shown in Figure 1A, compared
with INF, CP Ag+ had significantly higher levels of MMP-8 (GM
of 38.2 ng/ml in CP Ag+ vs. 10.9 in INF; P,0.0001) and MMP-9
(GM of 344.8 ng/ml in CP Ag+ vs. 113.2 in INF; P= 0.0098) and
significantly decreased levels of MMP-7 (GM of 2.7 ng/ml in CP
Ag+ vs. 6.7 in INF; P,0.0001). Similarly, as shown in Figure 1B,
CP Ag2 had significantly higher levels of MMP-1 (GM of 1.8 ng/
ml in CP Ag2 vs. 0.7 in EN; P,0.0001), MMP-7 (GM of 8.2 ng/
ml in CP Ag2 vs. 3.7 in EN; P= 0.0001), MMP-8 (GM of 8.7 ng/
ml in CP Ag2 vs. 1.9 in EN; P,0.0001) and MMP-9 (GM of
66.8 ng/ml in CP Ag2 vs. 6.6 in EN; P,0.0001) in comparison to
EN. Finally, INF had significantly higher levels of all the four
MMPs compared to EN (data not shown). Thus, filarial
lymphedema with or without active infection is characterized by
elevated levels of circulating MMPs.
CP individuals exhibit increased circulating levels of
TIMP-1 and TIMP-2 and decreased levels of TIMP-3,
independent of infection status
To determine the relationship of TIMPs to development of
filarial lymphedema, we measured the plasma levels of TIMP-1, -
2, -3, and -4 in CP Ag+, INF, CP Ag2, and EN. As shown in
Figure 2A, CP Ag+ had significantly higher levels of TIMP-1 (GM
of 4.5 ng/ml in CP Ag+ vs. 3.4 in INF; P= 0.0045) and TIMP-2
(GM of 17.6 ng/ml in CP Ag+ vs. 8.1 in INF; P= 0.0004) but
significantly lower levels of TIMP-3 (GM of 48.3 ng/ml in CP
Ag+ vs. 553.7 in INF; P,0.0001) and TIMP-4 (GM of 9.9 ng/ml
in CP Ag+ vs. 16.1 in INF; P= 0.0005) in comparison to INF.
Similarly, as shown in Figure 2B, CP Ag2 had significantly higher
levels of TIMP-1 (GM of 3.3 ng/ml in CP Ag2 vs. 1.4 in EN;
P,0.0001), TIMP-2 (GM of 9.8 ng/ml in CP Ag2 vs. 2.8 in EN;
P,0.0001) and TIMP-4 (GM of 15.1 ng/ml in CP Ag2 vs. 4.5 in
EN; P,0.0001) but significantly lower levels of TIMP-3 (GM of
554.8 ng/ml in CP Ag2 vs. 650 in EN; P=0.0177) in comparison
to EN. Finally, INF had significantly higher levels of TIMP-1, 2
and 4 in comparison to EN (data not shown). Thus, filarial
lymphedema with or without active infection is characterized by
elevated levels of circulating TIMP-1 and TIMP-2 and decreased
levels of TIMP-3.
Figure 1. Filarial lymphedema is associated with elevated levels of MMPs. (A) Plasma levels of MMP-1, -7, -8, and -9 from filarial
lymphedema individuals with active infection [CP Ag+] (n=28) and asymptomatic infected [INF] (n = 74) individuals were measured by ELISA. (B)
Plasma levels of MMP-1, -7, -8 and -9 from filarial lymphedema individuals without active infection [CP Ag2] (n = 77) and endemic normal [EN] (n=73)
individuals were measured by ELISA. P values were calculated using the Mann-Whitney test.
doi:10.1371/journal.pntd.0001681.g001
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Altered MMP/TIMP ratios are more reflective of filarial
lymphedema with active infection
Because the increased levels of MMPs and TIMPs were not
specific to actively infected CP individuals and as MMP/TIMP ratios
are considered to be more reflective of the pro-fibrotic status [12], we
determined the ratios of the various MMPs to the four TIMPS. As
shown in Figure 3A, we observed significantly increased ratios of
MMP-1/TIMP-4 (P=0.0311) and MMP-8/TIMP-4 (P,0.0001) in
CP Ag+ compared to INF but not in CP Ag2 compared to EN.
Conversely, CP Ag+ exhibited significantly decreased ratios ofMMP-
1/TIMP-1 (P=0.0043), MMP-7/TIMP-1 (P=0.0004), and MMP-
7/TIMP-2 (P,0.0001) compared to INF, with no significant
difference being observed between CP Ag- and EN. No significant
differences were seen between the CP groups and INF or EN group
in the ratio of other MMPs/TIMPs. Thus, an imbalance between the
circulating levels of specific MMPs and TIMPs—especially increased
MMP-1 and MMP-8 to TIMP-4 and decreased MMP-1 and MMP-
7 to TIMP-1 and 2—is characteristic of filarial lymphedema in the
presence of active infection.
CP individuals exhibit no significant alterations in the
levels of other pro-fibrotic factors
To determine the association of other pro-fibrotic factors with
filarial lymphedema, we measured the plasma levels of FGF-2 and
PDGF-AA in CP Ag+, INF, CP Ag2, and EN. As shown in
Figure 4A, CP Ag+ had no significant alterations in the levels of
FGF-2 or PDGF-AA in comparison to INF. Similarly, as shown in
Figure 4B, CP Ag2 had no significant alterations in the levels of
FGF-2 or PDGF in comparison to EN. Thus, filarial lymphedema
with or without active infection is not associated with alterations in
levels of pro-fibrotic factors FGF-2 or PDGF-AA.
CP Ag+ exhibit elevated levels of pro-fibrotic cytokines –
IL-5, IL-13 and TGF-b compared with INF
To determine the contribution of Type-2 and pro-fibrotic
cytokines to the process of filarial lymphedema, we measured the
plasma levels of IL-5, IL-13, and TGF-b in the four groups of
subjects. As shown in Figure 5A, compared with INF, CP Ag+ had
significantly higher levels of IL-5 (GM of 1019 pg/ml in CP Ag+
vs. 37.9 in INF; P,0.0001), IL-13 (GM of 1022 pg/ml in CP Ag+
vs. 40.8 in INF; P,0.0001), and TGF-b (GM of 308.2 pg/ml in
CP Ag+ vs. 231.6 in INF; P= 0.0160). As shown in Figure 5B, no
significant differences were observed in the levels of IL-13 or TGF-
b between those without active infection, irrespective of clinical
status. In addition, INF had significantly higher levels of IL-5 and
TGF-b compared to EN (data not shown). Thus, filarial
lymphedema with active infection is characterized by elevated
plasma levels of IL-5, IL-13, and TGF-b.
Figure 2. Filarial lymphedema is associated with elevated levels of TIMP-1 and 2. (A) Plasma levels of TIMP-1, -2, -3, and -4 from filarial
lymphedema individuals with active infection [CP Ag+] (n=28) and asymptomatic infected [INF] (n = 66–76) individuals were measured by ELISA. (B)
Plasma levels of TIMP-1, -2, -3, and -4 from filarial lymphedema individuals without active infection [CP Ag2] (n = 66–76) and endemic normal [EN]
(n = 73) individuals were measured by ELISA. P values were calculated using the Mann-Whitney test.
doi:10.1371/journal.pntd.0001681.g002
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Figure 3. Altered MMP to TIMP ratios in filarial infection and lymphedema. (A) Ratio of circulating levels of MMP-1/TIMP-4 and MMP-8/
TIMP-4 from filarial lymphedema individuals with active infection [CP Ag+] and asymptomatic infected [INF] individuals as well as from filarial
lymphedema individuals without active infection [CP Ag2] and endemic normal [EN] individuals are shown. (B) Ratio of circulating levels of MMP-1/
TIMP-2, MMP-7/TIMP-1, and MMP-7/TIMP-2 from filarial lymphedema individuals with active infection [CP Ag+] and asymptomatic infected [INF]
individuals as well as from filarial lymphedema individuals without active infection [CP Ag2] and endemic normal [EN] individuals are shown. P values
were calculated using the Mann-Whitney test.
doi:10.1371/journal.pntd.0001681.g003
MMPs/TIMPs in Filariasis
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Relationships between Type 2 cytokines and MMP/TIMP
ratios in infected individuals
The relationships among the Type-2 cytokines and MMP/
TIMP ratios were assessed in those subjects with active infection
(CP Ag+ and INF). As shown in Figure 6, plasma levels of IL-13
exhibited a significant positive correlation with the circulating
levels of MMP-1/TIMP-4 (r = 0.4477; P,0.0001) and MMP-8/
TIMP-4 (r = 0.4030, P,0.0001) in actively infected individuals.
Similarly, plasma levels of IL-5 exhibited a significant positive
correlation with the MMP-8/TIMP-4 (r = 0.4768, P,0.0001).
Thus, the altered balance between MMPs and TIMPs in the
circulation appears to be significantly associated with the Type-2
pro-fibrotic cytokine levels in filarial infection.
Discussion
The dynamics of the ECM in tissues are orchestrated by the
interplay among matrix breakdown, matrix deposition, and
reorganization. MMPs are a family of zinc-metalloendopeptidases
responsible for the turnover of ECM [12–14]. MMPs are tightly
regulated at multiple levels including transcriptional and transla-
tional regulation as well as by TIMPs [12]. Therefore, tissue
homeostasis is achieved by a tight balance of MMP proteolysis to
TIMP production. When this balance is altered by inflammation
and other mechanisms, dysregulated MMP activity ensues [12].
Altered MMP/TIMP expression ratios have been associated with
many diseases including: those associated with tissue destruction,
such as cancer invasion and metastasis [16], rheumatoid arthritis
[17], osteoarthritis [18]; those associated with fibrosis, such as liver
cirrhosis [19], scleroderma [20], systemic sclerosis [21]; and those
associated with weakening of the extracellular matrix, such as
dilated cardiomyopathy and epidermolysis bullosa [12].
Although some parasitic infections can induce fibrosis, few
studies have actually examined the role of MMPs and TIMPs in
human parasitic infections. MMPs and TIMPs have been shown
to be associated with disease activity in human neurocysticercosis
[22], leishmaniasis [23], schistosomiasis [24], and eosinophilic
meningitis [25]. In addition, the regulation of MMP activity has
been demonstrated in animal models of Schistosoma mansoni,
Toxoplasma gondii, Angiostrongylus cantonensis, Opistorchis viverrini, and
Mesocestoides cortii [15,26]. Interestingly, although skin and subcu-
taneous fibrosis and scarring is a characteristic feature associated
with longstanding LF and specifically elephantiasis, no study has
examined the regulation of MMPs and TIMPs in LF infection.
We utilized a cohort of clinically well defined individuals from
an area endemic for LF to examine the role played by MMPs and
Figure 4. Filarial lymphedema is not associated with elevated levels of FGF-2 or PDGF-AA. (A) Plasma levels of FGF-2 and PDGF-AA from
filarial lymphedema individuals with active infection [CP Ag+] (n=21–22) and asymptomatic infected [INF] (n = 22–39) individuals were measured by
ELISA. (B) Plasma levels of FGF-2 and PDGF-AA from filarial lymphedema individuals without active infection [CP Ag2] (n = 22–38) and endemic
normal [EN] (n = 21–33) individuals were measured by ELISA. P values were calculated using the Mann-Whitney test.
doi:10.1371/journal.pntd.0001681.g004
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TIMPs in filarial disease pathogenesis. We examined the
expression pattern of the pro-fibrotic factors using a two-step
comparison with the rationale that factors truly reflective of
infection-driven pathogenesis (as opposed to general factors) would
be significantly different between individuals with lymphedema/
elephantiasis with active infection and clinically asymptomatic but
actively infected individuals but not between those with disease
(CP) without active infection and uninfected, endemic normal
individuals. Our examination of the baseline levels of MMPs and
TIMPs revealed that both groups of proteins were non-specifically
elevated in individuals with chronic pathological consequences of
LF infection irrespective of their circulating filarial antigen level.
Therefore, this suggests that filarial disease per se (and not the
presence of viable parasites) is associated with these elevations in
ECM modulators; however, it also known that TIMPs mediate
blocking of MMP-induced proteolytic activity by noncovalently
binding to the MMP active site in a 1:1 stoichiometric ratio.
Therefore, we also examined the ratios of various MMPs to
TIMPs in our cohort of patients [27]. Not surprisingly, we found
evidence of an imbalance between MMPs and TIMPs. Our data
would therefore imply that altered ratios of MMP/TIMP are an
important underlying factor in the pathogenesis of tissue fibrosis in
filarial lymphatic disease. This process is reflective of imbalances in
the levels of MMP and TIMPs seen in other diseases with tissue
fibrosis, including systemic sclerosis [21], scleroderma [20],
amyotrophic lateral sclerosis [28], coronary artery disease [29],
endometriosis [30], rheumatoid arthritis [17], viral hepatitis [31],
and a variety of cancers [16]. Our data also suggest that currently
available synthetic MMP inhibitors could potentially be of benefit
in ameliorating pathology or preventing the development of
pathology in active infection [32]. In the context of a role for
infection per se, we observed that the presence of active infection
significantly enhanced the levels of most MMPs and TIMPs,
suggesting that changes in ECM remodeling are occurring prior to
the onset of clinically evident lymphedema.
Interestingly, among the MMPs with enhanced baseline
expression in filarial lymphedema are the two major collagenases
in the MMP family, MMP-1 (or collagenase-1) and MMP-8 (or
collagenase-2) [12]. While collagenases are known to degrade
collagen, MMP-9 is also a gelatinase that can degrade collagen as
well as gelatin [12]. As these proteolytic enzymes mainly target
collagen and because collagen has been previously shown to be
altered in filarial lymphatic pathology [7–9], it is interesting to
note that these enzymes are specifically elevated in chronic
pathology individuals irrespective of their infection status. In
addition to their role in ECM remodeling, TIMPs are also known
Figure 5. Circulating levels of pro-fibrotic cytokines in filarial lymphedema. (A) Plasma levels of IL-5, IL-13, and TGF-b from filarial
lymphedema individuals with active infection [CP Ag+] (n=24) and asymptomatic infected [INF] (n = 90) individuals were measured by ELISA. (B)
Plasma levels of IL-5, IL-13, and TGF-b from filarial lymphedema individuals without active infection [CP Ag2] (n = 70–91) and endemic normal [EN]
(n = 68–80) individuals were measured by ELISA. P values were calculated using the Mann-Whitney test.
doi:10.1371/journal.pntd.0001681.g005
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to have MMP-independent functions [27]. TIMP-3 is an
antagonist of vascular endothelial growth factor receptor-2
(VEGFR-2) [33], while TIMP-2 has been shown to antagonize
VEGF signaling [34], resulting in inhibition of angiogenesis.
Because lymphangiogenesis is a well described feature of filarial
lymphedema [2], it is of interest to note the significantly deceased
production of TIMP-3 as well as decreased levels of MMP/TIMP-
2 ratios in filarial lymphedema. The decreased levels of TIMP-3
and the decreased MMP/TIMP-2 ratios therefore, could poten-
tially signify an important role for these enzymes in promoting
VEGF-mediated angiogenesis and/or lymphangiogenesis in re-
sponse to inflammation, as has been described in neuroinflamma-
tory disorders such as multiple sclerosis or experimental autoim-
mune encephalomyelitis [27]. We plan to explore the functional
activity of MMPs and TIMPs in future experiments.
While MMPs and TIMPs are major regulators of fibrosis,
PDGF, FGF, epidermal growth factor (EGF), VEGF, and bone
morphogenic proteins (BMPs) are also known to influence tissue
fibrosis [11]. By examining expression of PDGF-AA and FGF-2 in
filaria-infected and filaria-uninfected individuals, we were able to
show that neither PDGF nor FGF was associated with filarial
lymphedema. These data suggest that while filarial lymphedema is
characterized by alterations in certain pro-fibrotic factors such as
MMPs/TIMPs, it is not associated with a generic increase in the
circulating levels of other factors known to influence tissue fibrosis.
Although persistent and progressive fibrosis is postulated to be a
hallmark of LF disease, the data on the known pro-fibrotic
cytokines in filarial disease are limited. By quantifying IL-5, IL-13,
and TGF-b levels in the four well defined groups, our data indicate
clearly that these particular cytokines are associated with
development of overt pathology in actively infected individuals.
Because pro-fibrotic cytokines are known to influence tissue
fibrosis by regulating the levels of MMPs and TIMPs [35–38], we
also examined the association between these factors. In agreement
with studies in animal models of parasitic infection showing
association between MMP/TIMP levels and Type 2 cytokines
[39–42], our examination of filaria-infected individuals also reveals
a significantly positive association between MMP-1/TIMP-4 and
MMP-8/TIMP-4 ratios (both of which were specifically elevated
in CP Ag+) and Type 2 (and pro-fibrotic) cytokines. Our study
clearly implicates a tissue-fibrosis promoting role for IL-5 and IL-
13 in filaria-induced lymphatic pathology.
Our study clearly identifies a novel role for MMPs and TIMPs
as well as Type 2 cytokines in filarial infection-driven morbidity
associated with a persistent and progressive tissue fibrosis. While
requiring validation in future studies, these results point to
Figure 6. Correlation between MMP/TIMP ratios and Type 2 cytokines in filaria-infected individuals. (A) MMP/TIMP ratios were
correlated with the levels of IL-13 from individuals with active infection [CP Ag+ and INF (n= 102–114)]. (B) MMP/TIMP ratios were correlated with the
levels of IL-5 from individuals with active infection [CP Ag+ and INF (n=102–114)]. CP Ag+ individuals are shown in gray circles and INF in dark circles.
P and r values were calculated using the Spearman rank correlation test.
doi:10.1371/journal.pntd.0001681.g006
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potential therapeutic interventional targets in ameliorating filarial
lymphedema and possibly even elephantiasis.
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